Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Fig. 3

Time to sustained deterioration of QLQ-C30 scales. CI confidence interval; DOC docetaxel, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, N number of patients, HR hazard ratio, PL placebo, QoL quality of life; RAM ramucirumab. Forest plot of time to sustained deterioration, HRs (unstratified) for each functional and symptom scale are depicted. HRs were estimated using a Cox regression model. 2-sided p-values were based on normal approximation

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us